EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Akebia Therapeutics's enterprise value is $972.9 Mil.
Akebia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $184.9 Mil. Therefore, Akebia Therapeutics's EV-to-Revenue for today is 5.26.
The historical rank and industry rank for Akebia Therapeutics's EV-to-Revenue or its related term are showing as below:
AKBA'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.35 Med: 1.48 Max: 93.5
Current: 5.26
During the past 13 years, the highest EV-to-Revenue of Akebia Therapeutics was 93.50. The lowest was -0.35. And the median was 1.48.
AKBA's EV-to-Revenue is ranked worse than 74.59% of 964
companies
in the Drug Manufacturers industry
Industry Median: 2.52
vs AKBA: 5.26
The historical data trend for Akebia Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akebia Therapeutics's EV-to-Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics's EV-to-Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's EV-to-Revenue falls into.
Akebia Therapeutics's current Enterprise Value is $972.9 Mil.
Akebia Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $184.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics's share price for today is $3.93.
Akebia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.84.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Akebia Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKBA has been successfully added to your 